Alterity Therapeutics Phase 2 Trial Continues as Planned
Ticker: PRNAF · Form: 6-K · Filed: May 9, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | May 9, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, drug-development, regulatory-update
TL;DR
Alterity's Phase 2 MSA drug trial gets green light from DMC to proceed as planned.
AI Summary
Alterity Therapeutics Ltd. announced on May 9, 2024, that its Phase 2 clinical trial for its lead drug candidate, ATH434, will continue as planned. The Data Monitoring Committee (DMC) recommended no changes to the trial protocol, which is evaluating ATH434 for the treatment of Multiple System Atrophy (MSA). This decision is based on a review of the ongoing trial data.
Why It Matters
The DMC's recommendation to continue the trial without modification is a positive signal for the development of ATH434, a potential treatment for MSA, a rare and serious neurodegenerative disease.
Risk Assessment
Risk Level: medium — Clinical trial progress is subject to inherent risks, and the ultimate success of ATH434 in treating MSA is not guaranteed.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant and developer of ATH434
- ATH434 (drug_candidate) — Lead drug candidate being evaluated
- Multiple System Atrophy (MSA) (disease) — Condition being treated by ATH434
- Data Monitoring Committee (DMC) (committee) — Reviewed trial data and made recommendation
FAQ
What was the recommendation from the Data Monitoring Committee (DMC)?
The DMC recommended that the Phase 2 clinical trial for ATH434 continue as planned, with no changes to the protocol.
What condition is ATH434 being tested for?
ATH434 is being tested for the treatment of Multiple System Atrophy (MSA).
What is the significance of the DMC's recommendation?
The recommendation indicates that the interim data reviewed by the DMC did not raise safety concerns or suggest a need for protocol modifications, which is a positive development for the trial.
When was this announcement made?
The announcement was made on May 9, 2024, as part of a Form 6-K filing.
What is the company's principal executive office address?
The company's principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Stats: 193 words · 1 min read · ~1 pages · Grade level 11.7 · Accepted 2024-05-08 18:58:07
Filing Documents
- ea0205514-6k_alterity.htm (6-K) — 14KB
- ea020551401ex99-1_alterity.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-040963.txt ( ) — 37KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Phase 2 DMC Recommends Continuing Clinical Trial as Planned 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: May 8, 2024 2